Novo Nordisk has increased its bid for the US biotech company Metsera, a start-up focused on obesity treatments, in a bid to gain control of the company and gain an edge in the growing market for weight-loss drugs. This move comes as a response to Pfizer's own bid for Metsera. The competition between these pharmaceutical giants highlights the increasing demand for obesity treatments.